CymaBay Therapeutics, Inc.

CymaBay Therapeutics, Inc.verified

CBAY

Price:

$32.48

Market Cap:

$3.73B

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis (PBC), as well as has completed Phase 2b clinical study to treat patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladel...[Read more]

Industry

Biotechnology

IPO Date

2014-02-03

Stock Exchange

NASDAQ

Ticker

CBAY

The PE Ratio as of June 2024 (TTM) for CymaBay Therapeutics, Inc. (CBAY) is -32.81

According to CymaBay Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -32.81. This represents a change of -65.44% compared to the average of -94.94 of the last 4 quarters.

CymaBay Therapeutics, Inc. (CBAY) Historical PE Ratio (quarterly & annually)

How has CBAY PE Ratio performed in the past?

The mean historical PE Ratio of CymaBay Therapeutics, Inc. over the last ten years is -6.56. The current -32.81 PE Ratio has changed 49.88% with respect to the historical average. Over the past ten years (40 quarters), CBAY's PE Ratio was at its highest in in the December 2019 quarter at -1.15. The PE Ratio was at its lowest in in the June 2023 quarter at -346.09.

Quarterly (TTM)
Annual

Average

-6.56

Median

-4.17

Minimum

-23.81

Maximum

-1.29

CymaBay Therapeutics, Inc. (CBAY) PE Ratio by Quarter and Year

Discovering the peaks and valleys of CymaBay Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 667.40%

Maximum Annual PE Ratio = -1.29

Minimum Annual Increase = -79.51%

Minimum Annual PE Ratio = -23.81

Quarterly (TTM)
Annual
YearPE RatioChange
2023-23.81414.13%
2022-4.6378.50%
2021-2.59-68.08%
2020-8.13532.31%
2019-1.29-79.51%
2018-6.27-46.15%
2017-11.65667.40%
2016-1.52-26.22%
2015-2.06-44.55%
2014-3.71-70.48%

CymaBay Therapeutics, Inc. (CBAY) Average PE Ratio

How has CBAY PE Ratio performed in the past?

The current PE Ratio of CymaBay Therapeutics, Inc. (CBAY) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

-10.34

5-year avg

-8.09

10-year avg

-6.56

CymaBay Therapeutics, Inc. (CBAY) PE Ratio vs. Peers

How is CBAY’s PE Ratio compared to its peers?

CymaBay Therapeutics, Inc.’s PE Ratio is less than Day One Biopharmaceuticals, Inc. (-5.55), less than X4 Pharmaceuticals, Inc. (-1.50), less than Inozyme Pharma, Inc. (-3.52), less than Acumen Pharmaceuticals, Inc. (-2.49), greater than Mereo BioPharma Group plc (-79.27), less than Akero Therapeutics, Inc. (-7.33), less than Terns Pharmaceuticals, Inc. (-6.02), less than Madrigal Pharmaceuticals, Inc. (-12.43), greater than Viking Therapeutics, Inc. (-55.90), less than Biomea Fusion, Inc. (-1.37), less than Stoke Therapeutics, Inc. (-6.42), less than Homology Medicines, Inc. (-0.01), less than Gossamer Bio, Inc. (-0.71), less than 89bio, Inc. (-4.88), less than Pliant Therapeutics, Inc. (-3.77), greater than Arcellx, Inc. (-56.17), less than Kiniksa Pharmaceuticals, Ltd. (148.62), less than Structure Therapeutics Inc. (-22.62), less than Karuna Therapeutics, Inc. (-29.52), less than Phathom Pharmaceuticals, Inc. (-2.81),

Build a custom stock screener for CymaBay Therapeutics, Inc. (CBAY) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like CymaBay Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

CymaBay Therapeutics, Inc. (CBAY) and other stocks custom spreadsheet templates

The easiest way to analyze a company like CymaBay Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is CymaBay Therapeutics, Inc.'s PE Ratio?

How is the PE Ratio calculated for CymaBay Therapeutics, Inc. (CBAY)?

What is the highest PE Ratio for CymaBay Therapeutics, Inc. (CBAY)?

What is the 3-year average PE Ratio for CymaBay Therapeutics, Inc. (CBAY)?

What is the 5-year average PE Ratio for CymaBay Therapeutics, Inc. (CBAY)?

How does the current PE Ratio for CymaBay Therapeutics, Inc. (CBAY) compare to its historical average?